The average age of diagnosisis 66 years, and cases are seldom identified in individuals below40 years.2 Since the late 1990s, the incidenceof PCa has risen by 3–7% annually, with gradual improvementsin survival rates.3,4 Although this trend is attributableto multiple factors, it is proposed that the widespread introductionof prostate specific antigen (PSA)-based testing in the early 1990shad a significant influence.5,6 This is because PSAtests allow for earlier PCa diagnosis and can predict cancer recurrence,which significantly improves patient outcomes. Here, KLK3 is linked to posterior cortical atrophy.